Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 10Medulloblastoma 7Glioma 7Central Nervous System Neoplasms 7Lymphoma 6Astrocytoma 5Oligodendroglioma 4Recurrence 3Gliosarcoma 3Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Ependymoma 2Burkitt Lymphoma 2Uveal Melanoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Intraocular Lymphoma 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Temozolomide 1Nivolumab 1Lomustine 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Newly Diagnosed High Grade Glioma × Lomustine × Clear all
NCT03425292 2023-11-08

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Saint John's Cancer Institute

Phase 1 Completed
49 enrolled
CNS

Newly Diagnosed High Grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡